Skip to main content
. 2012 Nov 9;5(1):64–79. doi: 10.1002/emmm.201201544

Figure 1. CD4+CD25High regulatory T-lymphocytes (Tregs) are reduced in rapidly progressing ALS patients.

Figure 1

Shown are flow cytometric analyses of leukocytes from 54 ALS patients through all stages of disease and 33 control volunteers.

  1. Representative flow diagrams showing CD4+CD25High Tregs from a rapidly progressing ALS patient, a slowly progressing ALS patient, and a control volunteer.
  2. Box and whisker plots indicating that percent of CD4+CD25High Tregs in total leukocytes from ALS patients (mean = 0.692%, median = 0.610%) were not different when compared with control volunteers using the t-test (mean = 0.845%, median = 0.800%).
  3. When the ALS patients were separated based on the rate of disease progression into rapidly (AALS points per month ≥1.5; 26 patients) versus slowly (AALS points per month <1.5; 28 patients) progressing ALS patients, the percent of CD4+CD25High Tregs were reduced in rapidly progressing patients (mean = 0.573%, median = 0.495%) compared with slowly progressing patients (mean = 0.825%, median = 0.660%) and reduced compared with control volunteers (mean = 0.845%, median = 0.800%); slowly progressing patients were not different than controls. #p = 0.018 versus slowly progressing ALS patients; **p = 0.003 versus controls.
  4. Scatter plot with regression line demonstrating that the percent of CD4+CD25High T cells were inversely correlated with rate of ALS progression (R = 0.301; linear regression). Slowly progressing ALS patients = AALS points/month <1.5; rapidly progressing ALS patients = AALS points/month >1.5, at the time of collection. ALS patients early in disease = AALS score < 100; ALS patients late in disease = AALS score ≥100, at the time of collection. &p = 0.028.